Screening
Routine screening in asymptomatic patients is not indicated.
A significant proportion of patients with Budd-Chiari syndrome (BCS), particularly young women, who present with a normal haematocrit and a normal erythropoietin level will eventually develop a polycythaemia vera (PV) phenotype.[13][15][66]
The estimated prevalence of myeloproliferative neoplasms in patients with BCS is 30% to 50%; the majority being PV.[66] In this setting, it is reasonable to screen for the JAK2 V617F mutation. If the patient has the mutation, referral to a haematologist is indicated.
Use of this content is subject to our disclaimer